

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A process comprising

a) bringing together a reagent containing polyclonal antibodies made against a mixture of a plurality of proteomic cancer markers from different cancer cell lines, said mixture containing markers identified and markers not yet identified, with a human saliva sample
5 to form an assay sample, and

b) determining whether an immunological reaction has occurred in the assay sample.

2. (previously amended) A process as in claim 1 further wherein

an ELISA test is conducted on the assay sample and ELISA test results are produced to determine whether an immunological reaction has occurred in the assay sample, and wherein, in the ELISA test, the human saliva sample is coated on a plate prior to being brought together with the reagent.

3. (original) A process as in claim 2 wherein the ELISA test results are selected from titer and binding affinity and positive results are indicative of the occurrence of an immunological reaction in the assay sample.

4. (currently amended) A process as in claim 1 further comprising

a) providing a mixture of proteomic cancer markers from different types of cancer cells, said mixture containing proteomic cancer markers identified and markers not yet identified,

~~plurality of colonies of cancer cells, each colony being of a different cancer cell line;~~

- ~~b) extracting at least one proteomic cancer marker from each said colony and forming a mixture from the extracted proteomic cancer markers;~~
e) ~~b)~~ forming polyclonal antibodies against the mixture; and
d) ~~c)~~ forming the reagent from said polyclonal antibodies.

5. (canceled)

6. (currently amended) A process as in claim-5 1 wherein the different cancer cell lines comprise a breast cancer cell line, a liver cancer cell line, a colon cancer cell line, and an ovarian cancer cell line.

7. (canceled)

8. (currently amended) A process as in claim 7 1 wherein the polyclonal antibodies are produced in animals.

9. (original) A process as in claim 8 further comprising separating blood containing the polyclonal antibodies from the animals and separating serum containing the polyclonal antibodies therefrom.

10. (original) A process as in claim 9 further comprising forming the reagent from the serum.

11. (original) A process as in claim 1 further comprising centrifuging a human saliva specimen to separate out cells and mucin and collecting the supernatant to form the human saliva sample.

12. (original) A process as in claim 11 further comprising collecting the human saliva specimen.

13. (currently amended) A process as in claim 4 ~~1~~ further comprising combining at least a portion of each ~~colony of cells~~ cell line with a carrier fluid, agitating the carrier fluid to disrupt the cells and form a suspension, centrifuging the suspension to separate out cell debris and nuclei and collecting the supernatant to complete the extracting of the ~~at least one~~ plurality of proteomic cancer ~~marker~~ markers from each ~~colony~~ cell line.

14. (original) A process as in claim 13 further comprising conducting the centrifuging step in two stages, to separate out cell debris in the first stage and nuclei in the second stage, and introducing a portion of the supernatant into the animals to be used to form the polyclonal antibodies.

15. (previously amended) A process as in claim 1 wherein the reagent contains a plurality of antibodies made against a plurality of proteomic cancer markers.

16. (currently amended) A non-invasive cancer screening method comprising

a) obtaining a saliva specimen from a patient,

b) forming a saliva sample from the saliva specimen,

c) bringing the saliva sample together with a reagent containing polyclonal antibodies

made against a plurality of proteomic cancer markers, some identified and others not yet identified, from different types of cancer cells to form an assay sample; and

d) determining whether an immunological reaction has occurred in the assay sample.

17. (previously amended) A method as in claim 16 wherein the step of determining is carried out by simple ELISA test to obtain ELISA test results, and wherein, in the simple ELISA test, the saliva sample is coated on a plate prior to being brought together with the reagent .

18. (currently amended) A method as in claim 17 wherein the ELISA test results are selected from titer and binding affinity and positive results are indicative of the occurrence of an immunological reaction in the assay sample, and

wherein the plurality of proteomic cancer markers from different types of cancer cells comprise proteomic cancer cell markers made from ~~at least two cell lines selected from~~ the group consisting of a breast cancer cell line, a lung cancer cell line, a stomach cancer cell line, a liver cancer cell line, a colon cancer cell line, an ovarian cancer cell line, a cervical cancer cell line, a mouth/pharynx cancer cell line, a skin cancer cell line, a pancreatic cancer cell line, a testes cancer cell line, a brain tumor cell line, and a prostate cancer cell line .

19. (original) A method as in claim 18 wherein obtaining ELISA test results above a predetermined value are indicative of a positive screening test for cancer.

20. (currently amended) A method as in claim 19 further comprising, in a case where the ELISA test results are above the predetermined value,

a) obtaining a second saliva specimen from the patient,

b) forming a second saliva sample from the second saliva specimen,

c) separating the second saliva sample into a plurality of portions,

d) bringing the portions of the second saliva sample together with a plurality of second reagents, a single reagent being brought together with each portion, each reagent

containing a separate slate of polyclonal antibodies made against proteomic cancer markers from different types of cancer cells, one type of cancer cells being used to form each slate of polyclonal antibodies, to form a plurality of assay samples;

e) conducting a simple ELISA test on each of the plurality of assay samples to obtain an ELISA test result on each of the plurality of assay samples,

f) identifying a test result above a predetermined value, and

g) associating the identified test result with the type of cancer cells used to produce the antibodies yielding such results.

21. (currently amended) A cancer diagnostic method comprising

a) obtaining a saliva specimen from a patient,

b) forming a saliva sample from the saliva specimen,

c) separating the saliva sample into a plurality of portions,

d) bringing the portions of the saliva sample together with a plurality of reagents, a single reagent being brought together with each portion, each reagent containing a separate slate of polyclonal antibodies made against proteomic cancer markers identified and markers not yet identified from different types of cancer cells, one type of cancer cells being used to form each slate of antibodies, to form a plurality of assay samples;

e) conducting a simple ELISA test on each of the plurality of assay samples to obtain an ELISA test result on each of the plurality of assay samples,

f) identifying a test result above a predetermined value, and

g) associating the identified test result with the type of cancer cells used to produce the antibodies yielding such results to provide the diagnosis,

wherein, in the simple ELISA test, each portion of the saliva sample is coated on a plate prior to being brought together with the reagent .

22. (currently amended) A method for monitoring effectiveness of cancer treatment, said

method comprising

a) obtaining a first saliva specimen from a patient,

b) forming a first saliva sample from the first saliva specimen,

5 c) bringing the first saliva sample together with a reagent containing polyclonal antibodies made against ~~at least one proteomic cancer marker~~ identified and not yet identified proteomic cancer markers made from a single cancer cell line to form a first assay sample,

10 e) ~~d~~) conducting a simple ELISA test on the first assay sample to obtain a first ELISA test result on the first assay sample,

f) ~~e~~) treating the patient for a cancer represented by the cancer cell line used to make the proteomic cancer marker, and, after a period of time of at least one week,

g) ~~f~~) obtaining a second saliva specimen from the patient,

h) ~~g~~) forming a second saliva sample from the second saliva specimen,

15 i) ~~h~~) bringing the second saliva sample together with the reagent to form a second assay sample,

j) ~~i~~) conducting a simple ELISA test on the second assay sample to obtain a second ELISA test result on the second assay sample, and

20 k) ~~j~~) comparing the second ELISA test result with the first ELISA test result to determine the effectiveness of the cancer treatment,

wherein, in the first and second simple ELISA tests, the saliva samples are coated on a plate prior to being brought together with the reagent. -

23. (original) A method as in claim 22 wherein the ELISA test results are selected from titer and binding affinity and a lower value for the second test results is indicative of effective cancer treatment.